Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study.

Haghikia A, Haghikia A, Hellwig K, Baraniskin A, Holzmann A, Décard BF, Thum T, Gold R.

Neurology. 2012 Nov 27;79(22):2166-70. doi: 10.1212/WNL.0b013e3182759621. Epub 2012 Oct 17.

PMID:
23077021
2.

MicroRNAs in the CSF: macro-advance in MS?

Meinl E, Meister G.

Neurology. 2012 Nov 27;79(22):2162-3. doi: 10.1212/WNL.0b013e31827597d1. Epub 2012 Oct 17. No abstract available.

PMID:
23077022
3.

Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis.

Fenoglio C, Ridolfi E, Cantoni C, De Riz M, Bonsi R, Serpente M, Villa C, Pietroboni AM, Naismith RT, Alvarez E, Parks BJ, Bresolin N, Cross AH, Piccio LM, Galimberti D, Scarpini E.

Mult Scler. 2013 Dec;19(14):1938-42. doi: 10.1177/1352458513485654.

PMID:
24277735
4.

Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls.

Keller A, Leidinger P, Lange J, Borries A, Schroers H, Scheffler M, Lenhof HP, Ruprecht K, Meese E.

PLoS One. 2009 Oct 13;4(10):e7440. doi: 10.1371/journal.pone.0007440.

5.

Differential microRNA expression in blood in multiple sclerosis.

Søndergaard HB, Hesse D, Krakauer M, Sørensen PS, Sellebjerg F.

Mult Scler. 2013 Dec;19(14):1849-57. doi: 10.1177/1352458513490542. Epub 2013 Jun 17.

PMID:
23773985
6.

Proteomic pattern analysis discriminates among multiple sclerosis-related disorders.

Komori M, Matsuyama Y, Nirasawa T, Thiele H, Becker M, Alexandrov T, Saida T, Tanaka M, Matsuo H, Tomimoto H, Takahashi R, Tashiro K, Ikegawa M, Kondo T.

Ann Neurol. 2012 May;71(5):614-23. doi: 10.1002/ana.22633.

PMID:
22522477
7.

Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.

Avsar T, Korkmaz D, Tütüncü M, Demirci NO, Saip S, Kamasak M, Siva A, Turanli ET.

Mult Scler. 2012 Aug;18(8):1081-91. doi: 10.1177/1352458511433303. Epub 2012 Jan 17.

PMID:
22252467
8.

Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis.

Kuhle J, Leppert D, Petzold A, Regeniter A, Schindler C, Mehling M, Anthony DC, Kappos L, Lindberg RL.

Neurology. 2011 Apr 5;76(14):1206-13. doi: 10.1212/WNL.0b013e31821432ff. Epub 2011 Feb 23.

PMID:
21346223
9.

miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis.

Honardoost MA, Kiani-Esfahani A, Ghaedi K, Etemadifar M, Salehi M.

Gene. 2014 Jul 10;544(2):128-33. doi: 10.1016/j.gene.2014.04.069. Epub 2014 Apr 30.

PMID:
24792898
10.

Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma.

Baraniskin A, Kuhnhenn J, Schlegel U, Maghnouj A, Zöllner H, Schmiegel W, Hahn S, Schroers R.

Neuro Oncol. 2012 Jan;14(1):29-33. doi: 10.1093/neuonc/nor169. Epub 2011 Sep 21.

11.
12.

Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.

Gandhi R, Healy B, Gholipour T, Egorova S, Musallam A, Hussain MS, Nejad P, Patel B, Hei H, Khoury S, Quintana F, Kivisakk P, Chitnis T, Weiner HL.

Ann Neurol. 2013 Jun;73(6):729-40. doi: 10.1002/ana.23880. Epub 2013 Jul 8.

PMID:
23494648
13.

Increased prevalence of and gene transcription by Chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis.

Dong-Si T, Weber J, Liu YB, Buhmann C, Bauer H, Bendl C, Schnitzler P, Grond-Ginsbach C, Grau AJ.

J Neurol. 2004 May;251(5):542-7.

PMID:
15164186
14.

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.

Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F, Hillert J, Piehl F, Olsson T.

Mult Scler. 2011 Mar;17(3):335-43. doi: 10.1177/1352458510389102. Epub 2010 Dec 6.

PMID:
21135023
15.

Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis.

Fenoglio C, Cantoni C, De Riz M, Ridolfi E, Cortini F, Serpente M, Villa C, Comi C, Monaco F, Mellesi L, Valzelli S, Bresolin N, Galimberti D, Scarpini E.

Neurosci Lett. 2011 Oct 17;504(1):9-12. doi: 10.1016/j.neulet.2011.08.021. Epub 2011 Aug 19.

PMID:
21875645
16.

Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis.

Verbeek MM, Notting EA, Faas B, Claessens-Linskens R, Jongen PJ.

Acta Neurol Scand. 2010 May;121(5):309-14. doi: 10.1111/j.1600-0404.2009.01242.x. Epub 2009 Nov 19.

PMID:
19925532
17.

Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry.

Teunissen CE, Koel-Simmelink MJ, Pham TV, Knol JC, Khalil M, Trentini A, Killestein J, Nielsen J, Vrenken H, Popescu V, Dijkstra CD, Jimenez CR.

Mult Scler. 2011 Jul;17(7):838-50. doi: 10.1177/1352458511399614. Epub 2011 Apr 19.

PMID:
21505015
18.

Human kallikrein 6 cerebrospinal levels are elevated in multiple sclerosis.

Hebb AL, Bhan V, Wishart AD, Moore CS, Robertson GS.

Curr Drug Discov Technol. 2010 Jun;7(2):137-40.

PMID:
20836755
19.

CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.

Romme Christensen J, Börnsen L, Khademi M, Olsson T, Jensen PE, Sørensen PS, Sellebjerg F.

Mult Scler. 2013 Jun;19(7):877-84. doi: 10.1177/1352458512466929. Epub 2012 Nov 24.

PMID:
23178691
20.

Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing.

Keller A, Leidinger P, Steinmeyer F, Stähler C, Franke A, Hemmrich-Stanisak G, Kappel A, Wright I, Dörr J, Paul F, Diem R, Tocariu-Krick B, Meder B, Backes C, Meese E, Ruprecht K.

Mult Scler. 2014 Mar;20(3):295-303. doi: 10.1177/1352458513496343. Epub 2013 Jul 8.

PMID:
23836875

Supplemental Content

Support Center